The tumor suppressor in lung cancer-1 (TSLC1) is a candidate tumor suppressor of lung cancer, and frequently inactivated in primary non-small cell lung cancer (NSCLC). In this study, we investigated the effects of TSLC1 mediated by a dual-regulated oncolytic adenovirus on lung cancer, and the mechanisms underlying the antitumor actions. Methods: The recombinant virus Ad·sp-E1A (∆24) -TSLC1 was constructed by inserting the TSLC1 gene into the dual-regulated Ad·sp-E1A (∆24) vector, which contained the survivin promoter and a 24 bp deletion within E1A. The antitumor effects of Ad·sp-E1A (∆24) -TSLC1 were evaluated in NCI-H460, A549, and H1299 lung cancer cell lines and the normal fibroblast cell line MRC-5, as well as in A549 xenograft model in nude mice. Cell viability was assessed using MTT assay. The expression of TSLC1 and activation of the caspase signaling pathway were detected by Western blot analyses. The tumor tissues from the xenograft models were examined using H&E staining, IHC, TUNEL, and TEM analyses. Results: Infection of A549 lung cancer cells with Ad·sp-E1A (∆24) -TSLC1 induced high level expression of TSLC1. Furthermore, the Ad·sp-E1A (∆24) -TSLC1 virus dose-dependently suppressed the viability of NCI-H460, A549, and H1299 lung cancer cells, and did not affect MRC-5 normal fibroblast cells. Infection of NCI-H460, A549, and H1299 lung cancer cells with Ad·sp-E1A (∆24) -TSLC1 induced apoptosis, and increased activation of caspase-8, caspase-3 and PARP. In A549 xenograft model in nude mice, intratumoral injection of Ad·sp-E1A (∆24) -TSLC1 significantly suppressed the tumor volume, and increased the survival rate (from less than 15% to 87.5% at d 60). Histological studies showed that injection of Ad·sp-E1A (∆24) -TSLC1 caused tumor cell apoptosis and virus particle propagation in tumor tissues. Conclusion: The oncolytic adenovirus Ad·sp-E1A (∆24) -TSLC1 exhibits specific antitumor effects, and is a promising agent for the treatment of lung cancer.
and 2009 by the SEER (Surveillance, Epidemiology and End Results) group at the National Cancer Institute in the USA, 219 440 patients were estimated to have primary lung and bronchial tumors in 2009, and 158 350 were estimated to have died as a result. Lung and bronchial tumors ranked the highest of all cancers in both the number of cases and the number of deaths. Currently, lung cancer is the most common primary malignant tumor, with over 1 million deaths worldwide occurring annually; this may in part be due to the increase in the population of smokers and environmental pollution. Thus, novel treatment methods for lung cancer are urgently needed, and these treatments must be highly effective and safe.
The Cancer Targeting Gene-Viro-Therapy (CTGVT) strategy developed by our group is one of the most promising approaches for cancer therapy [2] . The strategy combines the advantages of both gene therapy and virotherapy by using an oncolytic adenoviral vector (OA) harboring an anti-cancer gene. Currently, two main strategies are applied to construct the viral vector with oncolytic ability, which can specifically infect tumor cells but rarely infects normal cells [3] . The first strategy is to delete the adenoviral genes that are necessary for viral replication in normal cells but not in tumor cells. For example, the ONYX-015 and ZD55 oncolytic viruses were constructed by deleting the E1B gene, which functions in late viral RNA export [4] . The second strategy involves transcription targeting through the use of tumor-or tissue-selective promoters, which can control the expression of early viral genes such as E1A and/or E1B that are essential for replication. Our previous studies have shown that CTGVT exhibits greater antitumor effects than gene therapy or virotherapy alone [3, 5, 6] . The tumor suppressor in lung cancer-1 (TSLC1) was originally identified as a putative tumor suppressor for non-smallcell lung cancer (NSCLC) and was the first named tumor suppressor in lung cancer [7] . It is expressed in a variety of tissues and organs in the human body, particularly in the normal lung, brain, liver and skin [8] . The downregulation of the TSLC1 gene was frequently detected in various human cancers including gastric cancer [9] [10] [11] , hepatocellular carcinomas [12] , cervical cancer [13] , nasopharyngeal cancer [14] , breast cancer [15] , prostate cancer [16] , and pancreatic cancer [17] . TSLC1 is a transmembrane adhesion molecule that belongs to the immunoglobulin superfamily [18] , and it consists of an extracellular domain (EC), a transmembrane domain (TM) and a cytoplasmic domain (CP). The EC of TSLC1 mediates the formation of TSLC1 homodimers or heterodimers with other cell adhesion molecules, such as Necl-1, CRTAM, and Nectin-3, to regulate cell-cell adhesion. The CP interacts with DAL-1, another tumor suppressor gene, and membrane-associated guanylate kinase (MAGuK) homologs such as MPP3. The CP is able to regulate the activation of small Rho GTPases, thus acting as a vital connection between extracellular adhesion and intracellular signaling cascades. Furthermore, the possible molecular mechanisms of TSLC1 include the suppression of tumor formation, modulation of the cell cycle, pro-apoptotic activity and regulation of the epithelial-mesenchymal transition (EMT) [19] . Human survivin, the smallest member of the inhibitor of apoptosis protein (IAP) family, plays a key role in both the regulation of cell division and in the inhibition of apoptosis [20, 21] . Of significance, survivin has aberrantly high expression in cancer cells such as lung cancer but little expression in most normal tissues, making survivin an attractive anticancer target [22, 23] . Recent studies have shown that a designed oncolytic adenovirus driven by the survivin promoter exhibited a tumor-selective antitumor effect in vitro and in vivo [3, 24, 25] , suggesting that the survivin promoter is a good candidate for cancer therapy. To improve the OA tumor-specificity, a 24 bp region within the E1A conserved region 2 (CR2), which is responsible for binding the retinoblastoma (Rb) protein, was deleted. This deletion restricts viral replication to dividing cells or Rb-inactive and arrested cells [3] . In this study, the dual-regulated Ad·sp-E1A (∆24) oncolytic virus contained the 24 bp deletion within E1A and was driven by the survivin promoter. Previous studies demonstrated that TSLC1, a candidate tumor suppressor in lung cancer, was depleted or not expressed in lung cancer cells [7, 26] . Thus, it was inserted into the Ad·sp-E1A (∆24) OA, yielding the Ad·sp-E1A (∆24) -TSLC1 construct. Our data indicated that Ad·sp-E1A (∆24) -TSLC1 specifically induces dramatic cytotoxicity in lung cancer cells in vitro and effectively suppresses xenografted lung cancer in nude mice, suggesting that Ad·sp-E1A (∆24) -TSLC1 may be a promising therapeutic agent for lung cancer.
Materials and methods
Cell lines and culture conditions HEK293 (human embryonic kidney cell line containing the E1A region of Ad5) cell was obtained from Microbix Biosystem Inc (Toronto, Canada). All of the lung cancer cell lines (A549, NCI-H460, and H1299) and the normal lung cell line MRC-5 were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA) or Shanghai Cell Collection (Shanghai, China). All cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 4 mmol/L glutamine, 50 U/mL penicillin and 50 mg/mL streptomycin. All cell lines were cultured at 37 °C in 5% CO 2 .
Plasmids
The pcDNA3-hygro-TSLC1 plasmid was graciously provided by Dr R STEENBERGEN at the Vrije Universiteit Medical Center (Amsterdam, Netherlands). The pXC2 adenovirus shuttle vector, pMD-T, and the pBHGE3 adenoviral packaging vector were constructed in our laboratory. The pXC2·sp-E1A (∆24) OA plasmid was previously constructed in our laboratory [3] . The TSLC1 cDNA sequence was first cloned between the EcoR I and Xho I sites in the pMD-T vector to yield pMD-T-TSLC1. Then, pXC2·sp-E1A (∆24) -TSLC1 was constructed by inserting the entire TSLC1 expression cassette derived from pMD-T-TSLC1 into the Sal I site of the pXC2·sp-E1A (∆24) vector. All plasmid constructs were confirmed by restriction enzyme digestion, PCR and DNA sequencing.
Quantitative RT-PCR Total RNA was isolated from prepared lung cancer cells or normal cells with TRIzol reagent (Invitrogen, USA) according to the manufacturer's instructions. For the analysis of Survivin and TSLC1 expression, cDNA was synthesized using Moloney murine leukemia virus reverse transcriptase (Invitrogen, USA) as described by the manufacturer. Quantitative real-time PCR was performed using a SYBR Green kit (TOYOBA, Japan). The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) housekeeping gene was used for normalization. The following primers were used: TSLC1 forward primer, 5'-CGGCT- Generation, identification, purification, and titration of adenovirus Ad·sp-E1A (∆24) -TSLC1 and Ad·sp-E1A (∆24) viral vectors were generated by homologous recombination of pXC2·sp-E1A (∆24) -TSLC1 and pXC2·sp-E1A (∆24) , respectively, with the PBHGE3 adenoviral packaging vector in HEK293 cells. Individual plaques were selected and used to infect HEK293 cells. After observing cytopathic effects, the cell culture medium was collected and viral genomic DNA was extracted. Then, wild-type adenovirus and foreign gene expression cassettes were identified by PCR methods using primer pairs complementary to the E1A region or an exogenous gene. Recombinant adenoviruses were amplified in HEK293 cells and purified by cesium chloride gradient ultracentrifugation. Viral titers were determined by TCID50 (median tissue culture infective dose) assays in HEK293 cells.
Cell viability assay
Cells were plated in 96-well plates and treated with different recombinant adenoviruses at the following MOIs: 0.5, 1, 2, 5, and 10 for 48 h. Then, 20 μL of MTT (Sigma, USA) solution (5 mg/mL) was added to each well. Cells were incubated at 37 °C for 4 h. The supernatant of each well was carefully removed, and an equal amount of DMSO (150 μL) was added to each well and mixed thoroughly on a shaker for 10 min. The absorbance of each well was read at 595 nm with a DNA microplate reader (GENios model, Tecan; Maennedorf, Switzerland).
Cytopathic effect (CPE) assay NCI-H460, A549, and H1299 lung cancer cell lines and the normal fibroblast cell line MRC-5 were grown to subconfluence and infected with adenoviruses at various MOIs as described above. Six days after infection, a 2% crystal violet solution in 20% methanol was added to cells for 15 min and then washed with distilled water and photographed.
Hoechst 33342 staining
To detect chromatin condensation and nuclear fragmentation, which are characteristics of apoptosis, nuclei were stained with Hoechst 33342. A549, H1299, NCI-H460, and MRC-5 cells were infected with Ad·sp-E1A (∆24) and Ad·sp-E1A (∆24) -TSLC1 viruses at an MOI of 10 for 72 h. cells were fixed with 4% paraformaldehyde and then stained with the Hoechst 33342 staining kit (Beyotime, Nantong, China) for 20 min as described in the manufacturer's protocol. Cells were then washed twice with PBS and visualized under a fluorescence microscope. Uninfected cells served as a control.
Western blot analysis
Western blot analysis was performed using standard protocols to determine the expression of various proteins. Cells were trypsinized, harvested and resuspended in lysis buffer (62.5 mmol/L Tris-HCl [pH 6.8], 2% SDS, 10 mmol/L glycerol and 1.55% dithiothreitol). The total protein concentration was determined using the BCA TM Protein Assay kit (Pierce, Rockford, IL, USA) as described by the manufacturer. Then, protein samples were separated by 10%-15% SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (Millipore, MA, USA). Membranes were blocked in a 5% BSA solution and incubated with primary antibodies. Proteins were detected using the appropriate secondary antibodies conjugated to fluorescent molecules and visualized with an Odyssey Infrared imaging system (LI-COR Biosciences Inc, Lincoln, NE, USA). Caspase-3 and caspase-8 antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). TSLC1, E1A, and PARP antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The GAPDH antibody was purchased from Bioworld Technology (Bioworld, MN, USA).
Animal experiments
All of the animal experiments were approved by the Institutional Animal Care and Use Committee and were performed in accordance with the rules of our institution. Female BALB/c nude mice (4-5 weeks old) were purchased from the Shanghai Experimental Animal Center (Shanghai, China). A549 cells were subcutaneously injected into the lower right flank of female nude mice, and a tumor xenograft model was established. Each group was composed of at least eight animals, and tumor growth was monitored and measured every 3 d with a Vernier caliper. Tumor volume (V) was calculated according to the formula: V(mm 3 )=1/2×length (mm)×width (mm 2 ). When tumors reached an average volume of 100-130 mm 3 , mice were randomly allocated to six groups and given a daily dose of 5×10 8 plaque-forming units (pfu) of various adenoviruses in 100 μL of PBS or PBS alone. Adenoviruses or PBS alone were administered intratumorally for 4 d. Tumors were harvested 4 d after the last treatment for histopathologic and immunohistochemical (IHC) analyses.
Immunohistochemistry
For IHC analysis, tumors were harvested 4 d post-treatment and fixed in 4% paraformaldehyde, embedded in paraffin and cut into 4-mm sections. These sections were stained with goat monoclonal anti-adenoviral hexon antibody at a dilution of 1:200. Slides were then washed with PBS and incubated with the avidin-biotin-peroxidase complex (ABC) reagent (Vector Laboratories, Burlingame, CA, USA) and detected with diaminobenzidine tetrahydrochloride solution containing 0.006% hydrogen peroxide. Hematoxylin was used as a counterstain. Tissue sections stained without primary antibodies were used as negative controls. TdT-mediated dUTP-biotin nick end-labeling (TUNEL) assay The TUNEL method was used to detect apoptotic cells. The in situ cell apoptosis detection kit (Roche, Palo Alto, USA) was used. The staining was performed according to the manufacturer's instructions. Tissue sections in the PBS-treated group were stained and served as negative controls. The TUNEL reaction preferentially labels DNA strand breaks generated during apoptosis and discriminates apoptosis from necrosis and primary DNA strand breaks induced by apoptotic agents.
Transmission electron microscopy (TEM) analysis
For electron microscopy analysis, tumor samples (1 mm 3 ) were fixed in a PBS mixture containing 2.5% glutaraldehyde overnight and then incubated in 1% osmium tetroxide for 1 h. Tissues were rinsed in ddH 2 O, dehydrated through a graded series of ethanol and propylene oxide and finally embedded in Epon 812 resin (Shell Chemicals, Houston, TX, USA). After examination of semithin sections, areas were selected and subjected to ultrathin sectioning. Sections collected on 200 mesh copper grids were contrasted with lead citrate and uranyl acetate, examined and photographed with a JEOL 100CX transmission electron microscope (JEOL, Akishima, Japan).
Statistical analysis
The statistical significance of experimental results was calculated by the analysis of variance (ANOVA) and Student's t-test. All data are expressed as the mean±standard deviation (SD). Results were considered statistically significant at P<0.05.
Results
Characteristics of the oncolytic adenovirus Ad·sp-E1A (∆24) -TSLC1 To investigate the expression level of survivin and the TSLC1 gene, we first performed quantitative PCR. The results demonstrated that TSLC1 was significantly downregulated in several lung cancer cell lines (H1299, A549, and NCI-H460) compared to normal human fibroblast cells (MRC-5, Figure  1B) . Conversely, survivin expression was cancer-specific and was detected in lung cancer cells ( Figure 1A) , which is consistent with previous reports [23, 24] . Based on these results, we constructed the dual-regulated Ad·sp-E1A (∆24) -TSLC1 viral vector in which the antitumor gene TSLC1 was inserted into Ad·sp-E1A (∆24) , which contains the survivin promoter and a 24 bp deletion within the E1A CR2 region (Figure 2A) . We detected the tumor-specific expression of adenovirus E1A and the TSLC1 transgene. The A549 lung cancer cell line was infected with Ad·sp-E1A (∆24) and Ad·sp-E1A (∆24) -TSLC1 at an MOI of 10 for 48 h, and the expression of E1A and TSLC1 was then detected. These results indicated that both Ad·sp-E1A (∆24) and Ad·sp-E1A (∆24) -TSLC1 induced strong E1A expression ( Figure 2B ), implying that they replicated well in lung cancer cells. Additionally, the TSLC1 construct strongly induced TSLC1 expression compared to the mock treatment and Ad·sp-E1A (∆24) control virus ( Figure 2C ). These results demonstrate that the oncolytic virus can mediate TSLC1 expression in cancer cells.
Tumor cell-specific cytotoxicity mediated by Ad·sp-E1A (∆24) -TSLC1 in vitro Next, we investigated the effect of Ad·sp-E1A (∆24) -TSLC1 on cell viability. The human lung cancer cell lines A549, NCI-H460, H1299, and the human normal fibroblast cell line MRC-5 were infected with Ad·sp-E1A (∆24) and Ad·sp-E1A (∆24) -TSLC1 at an MOI of 10, and cell proliferation was measured using the MTT assay. As shown in Figure 3 
Ad·sp-E1A (∆24) -TSLC1 selectively induces cell apoptosis in vitro
We also evaluated whether OA-mediated TSLC1 induces tumor-specific cell apoptosis in lung cancer cells. Treatment of cancer cells with Ad·sp-E1A (∆24) -TSLC1 led to increased apoptosis, which featured chromatin condensation, nuclear fragmentation and apoptotic bodies ( Figure 5A ). To assess whether the mechanism of apoptosis involved the caspase signaling pathway, Western blotting analysis was performed to detect the expression of caspase cascade proteins. Consistent with the above findings, increased activation of caspase-8, caspase-3 and PARP was detected in lung cancer cells treated with Ad·sp-E1A (∆24) -TSLC1 compared to mock-treated or Ad·sp-E1A (∆24) -treated cells ( Figure 5B ). These results suggest that TSLC1 induces tumor cell apoptosis via activation of the caspase pathway. Figure 6A , Ad·sp-E1A (∆24) -TSLC1 treatment significantly suppressed lung carcinoma development compared to PBS treatment (P<0.05). Furthermore, Ad·sp-E1A (∆24) - Figure 6B ). Only one of the eight mice treated with Ad·sp-E1A (∆24) -TSLC1 died within the first 65 d. Conversely, PBS-treated mice gradually died after 35 d, and the survival rate of these mice was less than 15%. Furthermore, 50% of the Ad·sp-E1A (∆24) -treated mice and 87.5% of the Ad·sp-E1A (∆24) -TSLC1-treated mice survived beyond the end of the experiment.
Pathological effects of Ad·sp-E1A (∆24) -TSLC1 on tumor inhibition in nude mice To detect cell death and the expression of TSLC1 and adenovirus hexon in tumor tissues, H&E staining and IHC analysis utilizing anti-TSLC1 and anti-hexon antibodies were performed following various treatments. H&E staining demonstrated that Ad·sp-E1A (∆24) -TSLC1 resulted in more severe cytopathic effects than Ad·sp-E1A (∆24) (Figure 7) . IHC staining confirmed the strong expression of both TSLC1 and adenovirus hexon protein in the tumor tissues following treatment with Ad·sp-E1A (∆24) -TSLC1 (Figure 7) , suggesting that the expression of TSLC1 increased as the oncolytic virus replicated in the tumor cells.
TUNEL assay results indicated that Ad·sp-E1A (∆24) -TSLC1 treatment induced more extensive apoptosis in tumor tissue than Ad·sp-E1A (∆24) or PBS treatment (Figure 7) . Morphological changes in tumor masses were also observed by TEM analysis ( Figure 8A ). Characteristics of apoptosis, including nuclear collapse, nuclear envelope disappearance, an increased nuclear-to-cytoplasmic ratio, nuclear deformation, the presence of heterochromatin and chromatin condensation were observed in tumors treated with Ad·sp-E1A (∆24) -TSLC1. In addition, the presence and replication of Ad·sp-E1A (∆24) and Ad·sp-E1A (∆24) -TSLC1 were observed in tumor tissues ( Figure  8B ). These results suggest that specific propagation of oncolytic viruses is involved in the inhibition of tumor growth.
Discussion
We developed the Cancer Targeting Gene-Viro-Therapy (CTGVT) strategy in 2001 [27] , and this strategy has shown promising anticancer effects. Tumor-selective oncolytic viruses have been used as vectors to deliver the antitumor gene in CTGVT. The strategy improves cancer therapy through the dual action of the therapeutic gene and the oncolytic virus itself. The oncolytic poxvirus JX-594, which delivers granulocyte macrophage-colony stimulating factor (GM-CSF), exhibited outstanding antitumor results in a clinical trial via viral oncolysis and tumor-specific anti-cancer immunity [28] . JX-594 could selectively infect, replicate and express its transgene in cancer tissues but did not affect normal tissue; JX-594 was delivered into human metastatic solid tumors via intravenous infusion [29] . The oncolytic adenovirus is the most customizable vector in clinical and preclinical studies for human cancer therapy due to several biological properties including ease of production, oncolysis ability and a large packaging capacity. Recently, additional modifications to the oncolytic virus were made to improve its targeting and application for cancer therapy. The early E1A protein is an essential factor for efficient adenoviral replication in host cells; thus, the modification of E1A is a preferred strategy. A 24 bp deletion within the E1A CR2 region allows the adenovirus to target the Rb pathway in cancer cells [30] . Moreover, the use of a tumor-specific promoter as a replacement for the E1A endogenous promoter improves the targeting of the oncolytic virus. The human telomerase reverse transcriptase (hTERT) promoter [31] , the α-fetoprotein (AFP) promoter [32, 33] and the differential display code 3 (DD3) promoter [34] have been extensively utilized in targeted cancer therapy. Survivin is a cancer gene and could potentially be useful for cancer diagnosis and therapy [20, 21, 35] . A previous study demonstrated that the survivin promoter was superior for cancer targeting when compared to the hTERT promoter [24] . Thus, the Ad·sp-E1A (∆24) dual-regulated adenoviral vector was constructed with the survivin promoter and the 24-bpdeleted E1A gene to induce cancer-specific cytotoxic effects. Figure 3 , 4, and 6). Therefore, the survivin promoter-controlled E1A containing the 24 bp deletion may be useful for CTGVT in future lung cancer clinical trials. Our results indicated that the expression of TSLC1 played a vital role in the cytotoxicity induced by Ad·sp-E1A (∆24) -TSLC1. TSLC1 is a cell adhesion molecule that potentially mediates the crosstalk between extracellular adhesion and intracellular signaling cascades through its interaction with additional tumor suppressors (eg, DAL4.1 and MPP1-3) [36] . Thus, TSLC1 mediates potential anti-cancer effects. Notably, our previous study reported that OA encoding TSLC1 exhibits significant antitumor effects on hepatocellular cancer cells [25] . The differences between these studies include the OA design and the cancer types investigated. The previous study utilized SD55-TSLC1, which contained TSLC1 inserted into the dualregulated OA; this vector also encoded E1A driven by the survivin promoter and included an E1B gene deletion. This construct was used to explore the inhibitory effect of TSLC1 on liver cancer growth. In this study, the oncolytic adenoviruses Ad·sp-E1A (∆24) and Ad·sp-E1A (∆24) -TSLC1 suppressed lung tumors, but the latter exerted the strongest effect both in vitro and in vivo (Figure 3 and 6) , indicating the powerful anticancer role of TSLC1. In addition, inactivating mutations in TSLC1 have been observed in human solid tumors. A mouse model containing a TSLC1 deletion was established, and these www.chinaphar.com Lei W et al Acta Pharmacologica Sinica npg mice exhibited increased tumorigenesis and died significantly faster than wild-type controls [37] . These results confirm that TSLC1 is indeed an optimal tumor suppressor gene candidate for cancer gene therapy. Furthermore, we detected the activation of apoptosis via the caspase-dependent pathway, which was induced by oncolytic virus-mediated TSLC1 expression in lung cancer cells ( Figure 5 ). Tumor growth of lung cancer xenografts was restricted to a small volume 30 d after Ad·sp-E1A (∆24) -TSLC1 was injected into the nude mouse ( Figure 6A ), suggesting that Ad·sp-E1A (∆24) -TSLC1 can be used as a potential treatment for lung cancer. In this study, high levels of TSLC1 expression were obtained by our dual-regulated oncolytic virus, which replicated selectively in lung cancer cells. The survivin promoter was employed to control E1A expression. The antitumor effects mediated by TSLC1 in our dualregulated oncolytic adenovirus were enhanced compared to the adenovirus-mediated TSLC1 that was previously reported for use in lung cancer [38] . This difference may be due to Ad·sp-E1A (∆24) -TSLC1-induced apoptosis and oncolysis by selective replication in lung cancer cells ( Figure 8B) . A recent study reported that the interaction of TSLC1 with its ligand CRTAM enhances the anti-tumor immune response to trichosanthin in a murine Lewis lung cancer model [39] . The role of TSLC1 in the activation of the host immune response requires further investigation. More recently, studies have reported that the TSLC1 gene is suppressed by microRNA-216a and microRNA10b, facilitating early carcinogenesis, invasion and migration in hepatocellular carcinoma [40, 41] . These other studies further validated the role of TSLC1 in cancer gene therapy.
In conclusion, we constructed a novel dual-regulated CTGVT oncolytic viral vector, Ad·sp-E1A (∆24) -TSLC1, containing a survivin promoter to control the expression of the E1A gene containing a 24 bp deletion. Ad·sp-E1A (∆24) -TSLC1 displayed excellent antitumor effects in both lung cancer cells and in a nude mouse model. This report may provide a new strategy for the treatment of lung cancer.
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